b fp---er, That should not happen until the chief fishhead hits the $100,000,000 sales that he made in a public statement all those years ago, were to happen " in a very short time ",
Printable View
Actually I dont recall seeing anything about this NCCN side of the requirements for recognition and validity.
Possibly its the removal of a major hurdle for PEB so the next few announcements may be very interesting.
CMS and Kaiser would hardly go the whole hog without it being written into the guidelines.
Nothing to hold those two back now?
Lets hope so.
I see that the price is now hovering around 20cps, roughly where I bought in back in 2012.
New Zealand's a frustrating country - full of good ideas which seldom come to anything. More potential than you can shake a stick at, but the execution and implementation just seems to never happen.
There are actually a lot of good stories out there - Xero, Diligent are two but there's also Serko, Gentrack, PushPay, ATM and many more which do not list on the market.
A lot of rubbish listed on the market which should never be listed in the first place - so investors need to be careful.
Where do we even start - Snakk, Plus SMS, Feltex, CBL, Intueri, Wynyard, Provenco, SeaDragon,Bliss, Tru Screen etc etc.
Two common themes which emerge from the failures - backdoor list & Forsyth (Clients are pesky flies) Barr!
It's July and the clock is ticking louder and louder - PEB will run out of cash by Nov at the latest.
All the announcements to date have no material impact on the ability of PEB to generate meaningful revenues and cashflow - all designed to get the sp up to do (yet another) CR.
Can see it a mile away! :t_down:
Yesterdays announcement will have a huge impact on their ability to generate meaningful revenues and cashflow.
Previously:
DD. "Gidday Fred, Any chance on a bit of uptake with cxBladder , you know our clinical validity."
Fred: "Sorry, Dave, cant do much about it until its in the guidelines, You know we cant operate outside them much even though we know how good it is."
Now:
DD: "Gidday Fred, Did you see where our test has been accepted into the guidelines?
Fred: Yeah, saw that Dave,send your rep over and we'd better have a chat.
So what on the CR?
Can always buy some back when they are making zillions. :)
Not much in the market of a reaction of share price to the announcement, and not flagged as material or price sensitive. Is this telling?
Ok, firstly I do hope they translate this into revenue.
Secondly, did anyone look into the NCCN? its a group of 28 cancer hospitals, largely affiliated with universities, I'm sure they have influence at being at the 'pointy end' of uptake of new technology (I can find PEBs submission to them from 2 years ago) but there are not the decision makers who actually pay the bills. The PR is also cautious enough not to imply that this is the case
If the next financials come out with a big jump in Rev then cool, but I think the days of fooling the market with a flashy update is past them....